Stifel raised the firm’s price target on uniQure (QURE) to $65 from $30 and keeps a Buy rating on the shares. The three-year AMT-130 data suggest a larger market opportunity and a higher probability of approval, the analyst tells investors in a research note. The firm thinks AMT-130 is set up well given the severity of Huntington’s, the strength of the AMT-130 efficacy data, and uniQure’s attained alignment with FDA ahead of the three-year data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target
- uniQure has leading candidate in Huntington’s, says H.C. Wainwright
- Leerink says uniQure stock could trade up 100% on HD study data
- PTC shares to see pressure on ‘compelling’ uniQure data, says Citi
- PTC Therapeutics down 3% after uniQure Huntington’s disease data